[8-K] Cue Biopharma, Inc. Reports Material Event

Rhea-AI Filing Summary

Cue Biopharma, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1 to this Current Report and the company states that the information is being "furnished" rather than "filed," so it is not subject to the liability provisions of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference. The registrant’s common stock trades on the Nasdaq Capital Market under the symbol CUE.

Insights

Financial Analyst

TL;DR: Routine earnings press release furnished; no financial figures here to evaluate performance or trend.

The filing indicates only that a press release with quarterly financial results for the period ended June 30, 2025 was furnished as Exhibit 99.1. Because this 8-K does not include revenue, profit, cash flow, guidance, or balance sheet metrics, there is insufficient data within the document to assess operating performance, margins, liquidity, or capital needs. Investors must review the referenced press release for material financial details before drawing conclusions.

Corporate Governance Expert

TL;DR: Standard disclosure practice—company furnished a press release and explicitly limited its incorporation and Section 18 liability.

The company’s statement that the press release is "furnished" and not "filed" is a routine legal distinction that limits statutory liability under Section 18 of the Exchange Act and prevents implicit incorporation by reference. This clarifies the legal status of the disclosure but has no substantive operational or financial content on its own. Stakeholders should consult Exhibit 99.1 for material information referenced by this report.

false000164546000016454602025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 12, 2025

Cue Biopharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38327		47-3324577
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

40 Guest Street Boston, Massachusetts		02135 (Zip Code)
(Address of principal executive offices)

(617) 949-2680

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CUE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.  

On August 12, 2025, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.		Description
99.1		Press Release dated August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Cue Biopharma, Inc.
Date: August 12, 2025				By:		/s/ Daniel R. Passeri
				Name: Daniel R. Passeri
				Title: Chief Executive Officer

FAQ

What did Cue Biopharma (CUE) disclose in this 8-K?

The company furnished a press release announcing financial results for the quarter ended June 30, 2025, included as Exhibit 99.1.

Is the press release in this 8-K considered "filed" with the SEC?

No. The company expressly states the press release is being furnished and not "filed," so it is not subject to Section 18 liabilities and is not incorporated by reference unless specifically referenced elsewhere.

Where can I find the full financial details for Q2 2025?

The full financial details should be in the press release furnished as Exhibit 99.1; this 8-K only notes the furnishing of that press release and does not include the financial figures.

What is Cue Biopharma’s ticker and exchange?

Cue Biopharma’s common stock trades on the Nasdaq Capital Market under the ticker CUE.

Does this 8-K report any other material transactions or financial statements?

No. The filing only furnishes a press release as Exhibit 99.1 and includes the Inline XBRL cover page as Exhibit 104; it does not include financial tables or other material transactions.